MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
81.2%−8.3 pts over 5 years
Operating margin
-157.1%−114.9 pts over 5 years
Net margin
-135.1%−90.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.5% | -9.3% | +4.8% | – | |
| Gross profit | -15.0% | -11.9% | +2.8% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -50.5% | -23.6% | |
| Return on assets | – | – | -20.2% | |
| Current ratio | – | 3.90 | 8.30 | |
| Interest coverage | – | -509.5× | – | |
| Inventory turnover | – | – | 0.8× | |
| Capex to revenue | – | 7.9% | 5.4% | |
| Diluted shares | – | 69M | 106M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Maxcyte generated $109.17M from operations and spent $29.43M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$109.17M
Used
$29.43M
Capital expenditure$29.43M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-135.1%
×Asset turnover0.15×
×Equity multiplier1.17×
=Return on equity, FY2025-23.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -135.1% | 0.15× | 1.17× | -23.6% |
| FY2024 | -106.3% | 0.15× | 1.16× | -18.7% |
| FY2023 | -91.8% | 0.15× | 1.14× | -15.6% |
| FY2022 | -53.3% | 0.16× | 1.10× | -9.1% |
| FY2021 | -56.3% | 0.20× | 1.13× | -12.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$44.63M
- Cash generatingOperating cash flow above zero-$34.41M
- Return on assets improvedROA up on the prior year-15.3% → -18.6%
- Earnings backed by cashOperating cash flow above net income-$34.41M vs -$44.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.88 → 8.30
- No dilutionShare count did not rise105M → 106M
- Gross margin improvedGross margin up on the prior year81.62% → 81.16%
- More efficientAsset turnover rose0.14 → 0.14